Patents Assigned to The Institutes of Medical Sciences
-
Publication number: 20130178762Abstract: A set of color coded rings consisting of one subset of even numbers and other subset of odd numbers together is indicative of serially increasing cervical dilatation from 4 cm. to 9 cm. Vaginal examination with all aseptic precautions is to be carried out every 2 to 4 hours for each delivering woman. Size and color of the ring corresponding to actual cervical dilatation is to be identified. Next ring of the same color indicates expected cervical dilatation at the end of every 2 hours. If the expected cervical dilatation is not reached within the stipulated period of time, it indicates slow progress of labor and need for intervention/referral. It is an alternative for cervicograph which is easy to understand and use by clinical as well as para-clinical personnel during delivery.Type: ApplicationFiled: January 5, 2012Publication date: July 11, 2013Applicant: KRISHNA INSTITUTE OF MEDICAL SCIENCES UNIVERSITYInventors: Asha Krishna PRATINIDHI, Krishna Shridharrao PATIL, Aparna Nishikant SHROTRI, Hemangi Parag KALE
-
Publication number: 20130167391Abstract: A caliper to measure foot length and corresponding category of birth weight group by four colors used on the measuring scale namely. Green as normal, yellow as low, orange as very low and red as extremely low birth weight is devised for the first time to be used at the community level. A metal caliper with concavity to accommodate convexity of the heel and sliding device perpendicular to the scale to touch the longest toe fix the two extreme ends. Thus direct measurement is possible between two extreme ends of the foot.Type: ApplicationFiled: January 4, 2012Publication date: July 4, 2013Applicant: KRISHNA INSTITUTE OF MEDICAL SCIENCES UNIVERSITYInventors: Asha Krishna PRATINIDHI, Abhijit BAGADE, Arvind KANHERE, Satish Vasant Kakade, Vinayak Yadavrao KSHIRSAGAR, Aditya Krishna PRATINIDHI, Hemangi Parag KALE
-
Publication number: 20130157950Abstract: The present invention was accomplished for the purpose of developing a method for effectively treating and/or preventing synucleinopathies, and is based on a discovery that an adiponectin receptor agonist suppresses ? (alpha)-synuclein aggregation, tau phosphorylation and a decrease in proteasomal activity. The method of the present invention for treating and/or preventing neurodegenerative diseases includes a step of administering an effective dose of at least one effective element selected from a group consisting of: adiponectin as an adiponectin receptor agonist; a compound inducing expression of adiponectin; globular adiponectin; and a compound inducing expression of globular adiponectin. The present invention further provides a screening method of the adiponectin receptor agonist for treating and/or preventing neurodegenerative diseases.Type: ApplicationFiled: August 20, 2012Publication date: June 20, 2013Applicant: TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCEInventors: Makoto HASHIMOTO, Kazunari SEKIYAMA, Yoshiki TAKAMATSU, Masayo FUJITA, Akio SEKIGAWA
-
Patent number: 8466273Abstract: The present invention aims to provide hepatitis C virus inhibitors capable of inhibiting viral replication in hepatitis C virus-infected cells. The replication of hepatitis C virus can be inhibited and hepatitis C virus-infected cells can be specifically injured by specifically inhibiting BGT-1 or AKR1C1 involved in the replication of hepatitis C virus. Thus, viral inhibitors comprising a substance inhibiting BGT-1 or AKR1C1 are effective for the treatment of hepatitis C.Type: GrantFiled: September 30, 2008Date of Patent: June 18, 2013Assignees: Juridical Foundation The Chemo-Sero-Therapeutic Research Institute, Tokyo Metropolitan Institute of Medical Science, National University Corporation Kumamoto UniversityInventors: Kyoko Kohara, Michinori Kohara, Tomohiro Nishimura, Masaaki Sato
-
Patent number: 8460912Abstract: The present invention provides a method for replicating efficiently an RNA containing fulllength HCV genomic sequence and a method for producing HCV virus particles containing fulllength HCV replicon RNA or fulllength HCV genomic RNA by using a cell culture system. Further, the present invention relates to a method for producing hepatitis C virus particles which comprises culturing a cell, into which a replicon RNA comprising a nucleotide sequence comprising a fulllength genomic RNA sequence of hepatitis C virus of the genotype 2a, at least one selectable marker gene and/or at least one reporter gene and at least one IRES sequence or the fulllength genomic RNA of hepatitis C virus of the genotype 2a is introduced, and generating virus particles in the culture medium. Still further the present invention relates also to a hepatitis C vaccine and an antibody against hepatitis C virus particles.Type: GrantFiled: August 21, 2009Date of Patent: June 11, 2013Assignees: Tokyo Metropolitan Institute of Medical Science, Toray Industries, Inc.Inventors: Takaji Wakita, Takanobu Kato, Tomoko Date, Michiko Miyamoto, Jun-ichi Tanabe, Saburo Sone
-
Patent number: 8454973Abstract: The present invention provides modified hepatitis C virus genomic RNA, comprising nucleotide sequences of genomic RNA portions of two or more types of hepatitis C viruses, which comprises a 5? untranslated region, a core protein coding sequence, an E1 protein coding sequence, a p7 protein coding sequence, an E2 protein coding sequence, an NS2 protein coding sequence, an NS3 protein coding sequence, an NS4A protein coding sequence, an NS4B protein coding sequence, an NS5A protein coding sequence, an NS5B protein coding sequence, and a 3? untranslated region, and which can be autonomously replicated. In particular, the present invention relates to modified hepatitis C virus genomic RNA, which can be autonomously replicated by substitution of the RNA sequence portion encoding NS3, NS4, NS5A, and NS5B proteins of hepatitis C virus genomic RNA with a partial RNA sequence encoding NS3, NS4, NS5A, and NS5B proteins of a JFH1 strain shown in SEQ ID NO: 1.Type: GrantFiled: August 24, 2005Date of Patent: June 4, 2013Assignees: Tokyo Metropolitan Institute of Medical Science, Toray Industries, Inc.Inventors: Takaji Wakita, Takanobu Kato, Tomoko Date, Michiko Miyamoto, Ralf Bartenschlager, Jun-ichi Tanabe, Saburo Sone
-
Publication number: 20130129738Abstract: Disclosed is an influenza virus infection inhibitor. Specifically disclosed is a pharmaceutical composition that is composed of an inhibitor such as an antibody which recognizes a peptide comprising the amino acid sequence of RERRRKKR (SEQ ID NO: 1) and inhibits the action of introducing an RR sequence into a cell. The influenza virus infection inhibitor is produced so as to contain the pharmaceutical composition.Type: ApplicationFiled: November 19, 2010Publication date: May 23, 2013Applicant: TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCEInventors: Futoshi Shibasaki, Akira Sakurai
-
Publication number: 20130122026Abstract: The present invention aims to provide a DNA vaccine for Alzheimer's disease. The present invention provides a recombinant vector which comprises DNA encoding amyloid ? and DNA encoding a Th2 cytokine, as well as a DNA vaccine for Alzheimer's disease which comprises this vector.Type: ApplicationFiled: January 17, 2013Publication date: May 16, 2013Applicant: TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCEInventor: TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE
-
Publication number: 20130115592Abstract: The present invention provides modified hepatitis C virus genomic RNA, comprising nucleotide sequences of genomic RNA portions of two or more types of hepatitis C viruses, which comprises a 5? untranslated region, a core protein coding sequence, an E1 protein coding sequence, a p7 protein coding sequence, an E2 protein coding sequence, an NS2 protein coding sequence, an NS3 protein coding sequence, an NS4A protein coding sequence, an NS4B protein coding sequence, an NS5A protein coding sequence, an NS5B protein coding sequence, and a 3? untranslated region, and which can be autonomously replicated. In particular, the present invention relates to modified hepatitis C virus genomic RNA, which can be autonomously replicated by substitution of the RNA sequence portion encoding NS3, NS4, NS5A, and NS5B proteins of hepatitis C virus genomic RNA with a partial RNA sequence encoding NS3, NS4, NS5A, and NS5B proteins of a JFH1 strain shown in SEQ ID NO: 1.Type: ApplicationFiled: January 4, 2013Publication date: May 9, 2013Applicants: TORAY INDUSTRIES, INC., TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCEInventors: Tokyo Metropolitan Institute Of Medical Science, Toray Industries, Inc.
-
Publication number: 20130078277Abstract: An objective of this invention is to provide an HCV strain with a high capacity for virus production in a cell culture system. This invention provides a nucleic acid encoding a polyprotein precursor of the hepatitis C virus JFH1 strain having one or more amino acid substitutions, wherein the polyprotein precursor comprises at least substitution of glutamine at position 862 with arginine, as determined with reference to the amino acid sequence as shown in SEQ ID NO: 2 in the Sequence Listing.Type: ApplicationFiled: March 25, 2011Publication date: March 28, 2013Applicants: THE UNIVERSITY OF TOKYO, NIHON UNIVERSITY, TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE, TORAY INDUSTRIES, INC., JAPAN AS REPRESENTED BY DIRECTOR-GENERAL OF NATIONAL INSTITUTE OF INFECTIOUS DISEASES, INSTITUTE OF MICROBIOLOGY, CHINESE ACADEMY OF SCIENCESInventors: Yoshihiro Kitamura, Yoko Shimizu, Chie Aoki, Lijuan Yu, Takaji Wakita
-
Patent number: 8383371Abstract: The present invention relates to a replicon RNA comprising a nucleotide sequence at least containing the 5? untranslated region, the nucleotide sequence encoding NS3 protein, NS4A protein, NS4B protein, NS5A protein and NS5B protein, and the 3? untranslated region on the genomic RNA of hepatitis C virus of genotype 2a.Type: GrantFiled: December 1, 2010Date of Patent: February 26, 2013Assignees: Toray Industries, Inc., Tokyo Metropolitan Institute of Medical ScienceInventors: Takaji Wakita, Takanobu Kato, Tomoko Date
-
Patent number: 8299232Abstract: A novel recombinant chimera of DNA construct having esat-6 region of Mycobacterium tuberculosis and kinesin region of Leishmania donovani cloned together on two sides of self cleaving peptide in a DNA vaccine vector pVAX-1 wherein the chimeric construct is operatively linked to a transcriptional promoter thus capable of self replication and expression within the mammalian cell, and the process of preparation thereof comprising: analysis of the predicted protein sequence of kinesin motor domain and esat-6 domain using Promiscuous MHC Class-1 Binding Peptide Prediction Servers; amplification of gene coding for kinesin motor domain and esat-6 domain; cloning of kinesin esat-6 gene region in pGEM-T™ vector for sequence analysis; generation of chimeric construct by directional cloning in pVAX-1 vector.Type: GrantFiled: February 10, 2009Date of Patent: October 30, 2012Assignees: Department of Biotechnology, All India Institute of Medical ScienceInventors: Sarman Singh, Ayan Dey
-
Publication number: 20120245050Abstract: [Problem] To provide a biomarker for predicting the therapeutic efficacy of allergen immunotherapy.Type: ApplicationFiled: October 25, 2010Publication date: September 27, 2012Applicants: NIPPON MEDICAL SCHOOL FOUNDATION, TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCEInventors: Takachika Hiroi, Kimihiro Okubo
-
Publication number: 20120231422Abstract: This invention relates to a novel non-obturation, regenerative technique “SealBio” of endodontic treatment involving regenerative potential of stem cells and signaling molecules, locally available in the peri-radicular region of teeth, wherein they are stimulated to induce healing and deposition of a natural barrier (seal) at the root apex.Type: ApplicationFiled: June 16, 2010Publication date: September 13, 2012Applicant: All Indian Institute of Medical SciencesInventors: Shah Naseem, Logani Ajay
-
Publication number: 20120204279Abstract: A polynucleotide encoding the amino acid shown in SEQ ID NO:2 or SEQ ID NO: 5, or encoding an amino acid sequence having not less than 98% identity thereto; preferably a polynucleotide comprising replacement of the amino acid corresponding to glutamic acid at position 1202 of SEQ ID NO:2 (position 177 of SEQ ID NO:5) with glycine, replacement of the amino acid corresponding to glutamic acid at position 1056 (position 31 of SEQ ID NO:5) with valine, and replacement of the amino acid corresponding to alanine at position 2199 (position 1174 of SEQ ID NO:5) with threonine.Type: ApplicationFiled: August 25, 2010Publication date: August 9, 2012Applicants: PHOENIXBIO CO., LTD., TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCEInventors: Michinori Kohara, Masaaki Arai, Chise Mukaidani
-
Patent number: 8183044Abstract: The present invention relates to a method for producing a recombinant hepatitis C virus-like particle comprising the steps of introducing into (i) a cell in which an RNA replicon comprising a nucleotide sequence comprising the 5? untranslated region, the nucleotide sequence coding for the NS3, NS4A, NS4B, NS5A, and NS5B proteins, and the 3? untranslated region of a genome RNA derived from a hepatitis C virus strain autonomously replicates, (ii) a vector expressing the Core, E1, E2, and p7 proteins derived from a hepatitis C virus strain that is the same as or different from that as defined in the above (i), culturing the cell, and recovering the produced virus-like particle, and a recombinant hepatitis C virus particle produced by this method.Type: GrantFiled: September 29, 2006Date of Patent: May 22, 2012Assignees: Japan as represented by Director-General of National Institute of Infectious Diseases, Tokyo Metropolitan Institute of Medical Science, Toray Industries, Inc.Inventors: Jun-ichi Tanabe, Saburo Sone, Takaji Wakita, Koji Ishii, Ryosuke Suzuki, Tetsuro Suzuki, Tatsuo Miyamura
-
Patent number: 8182987Abstract: An object of an embodiment of the present invention is to provide a method with which it is possible to easily distinguish a proliferation phase of a cell cycle from a resting phase thereof in real time. The object of the embodiment of the present invention is attained by providing a method for performing phase identification of the cell cycle, the method including: visualizing one or more gene-expression products as markers whose amounts in a cell change in a cell-cycle dependent manner; and detecting the products so as to distinguish the proliferation phase of the cell cycle from the resting phase thereof.Type: GrantFiled: February 6, 2008Date of Patent: May 22, 2012Assignees: Tokyo Metropolitan Institute of Medical Science, RikenInventors: Atsushi Miyawaki, Asako Sawano, Hisao Masai
-
Publication number: 20120115927Abstract: Disclosed is a pharmaceutical agent for preventing cell death. The occurrence of cell death can be prevented by inhibiting the function of Int6 protein in an affected area. Then, a pharmaceutical agent comprising a substance capable of inhibiting the function of Int6 protein is prepared. The pharmaceutical agent can be used for preventing cell death.Type: ApplicationFiled: March 23, 2010Publication date: May 10, 2012Applicant: TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCEInventors: Futoshi Shibasaki, Li Chen
-
Patent number: 8143022Abstract: The present invention relates to a method for producing infectious hepatitis C virus (HCV) particles, comprising a step of introducing an expression vector into a cell that allows HCV proliferation, such expression vector comprising: DNA sequences encoding the 5? untranslated region, structural proteins, and, if necessary, non-structural proteins of HCV and DNA sequences encoding non-structural proteins and the 3? untranslated region derived from the HCV JFH1 strain, which are located downstream of a polymerase I promoter; and a DNA fragment containing an RNA polymerase I terminator, which is located further downstream thereof.Type: GrantFiled: September 29, 2006Date of Patent: March 27, 2012Assignee: Tokyo Metropolitan Institute of Medical ScienceInventors: Jun-ichi Tanabe, Saburo Sone, Takaji Wakita, Koji Ishii, Ryosuke Suzuki, Tetsuro Suzuki, Tatsuo Miyamura
-
Publication number: 20120065198Abstract: The present invention provides a method for diagnosing schizophrenia, and a schizophrenia diagnostic reagent or device for use in the method. The present invention further provides a therapeutic or ameliorating agent for schizophrenia, which is effective for the treatment or amelioration of schizophrenia. The therapeutic or ameliorating agent for schizophrenia contains a carbonyl scavenger or a carbonyl-modified protein formation inhibitor as an active ingredient. The method for diagnosing schizophrenia according to the present invention includes measuring at least one parameter in a subject, the parameter being selected from the group consisting of: (1) a genetic abnormality of glyoxalase I gene; (2) the expression level or activity of glyoxalase I in a biological sample; (3) the amount of a carbonyl compound or a carbonyl-modified protein that is a protein modified with the carbonyl compound; and (4) the amount of pyridoxal in a biological sample.Type: ApplicationFiled: July 31, 2008Publication date: March 15, 2012Applicants: Tokai University Educational System, Tokyo Metropolitan Institute of Medical Science, Renascience Co., Ltd., Medical & Biological Laboratories Co., Ltd.Inventors: Masanari ITOKAWA, Toshio MIYATA, Makoto ARAI